Method for the establishment of a pluripotent human blastocyst - derived stem cell line

• US 20050095703A1
• Filed: 12/27/2002
• Published: 05/05/2005
• Est. Priority Date: 12/28/2001
• Status: Abandoned Application

• Current Assignee: Cellartis AB
• Original Assignee: Cellartis AB
• Inventors: Tonning, Anna, Semb, Henrik
• Application Number:
  US10/500,118
• Publication Number:
  US 20050095703A1
• Time in Patent Office: Days
• US Class Current: 435/366
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2501/905 Hyaluronic acid
• CPC Class Codes: C12N 2502/13 connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0618 Cells of the nervous system
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The present invention concerns a method for the establishment of pluripotent human blastocyst-derived stem (BS) cell lines, stem cells obtained by the method, differentiation of these cells into differentiated cells, the differentiated cells, and the use of these differentiated cells in the preparation of medicaments. The undifferentiated pluripotent stem cells can be made to differentiate to a number of specialized cell types which can be utilized in the manufacture of medicaments for treating a number of conditions or pathologies involving degeneration of tissue, e.g., of the pancreas leading to, e.g., development of diabetes, or of the CNS (e.g., Alzheimer'"'"'s, Parkinson'"'"'s disease, etc.) or degeneration of the CNS caused by e.g., stroke or physical trauma.

Claims

1. A method for obtaining a pluripotent human blastocyst-derived stem cell line comprising:

i) using a fertilized oocyte of grade 1 or 2 to obtain a blastocyst of grade A or B;

ii) co-culturing the blastocyst with feeder cells to establish one or more colonies of inner cell mass cells;

iii) isolating the inner cell mass cells by mechanical dissection; and

iv) co-culturing the inner cell mass cells with feeder cells to obtain a blastocyst-derived stem cell line.

5. The method of claim 1, wherein the blastocyst in step i) is a spontaneously hatched blastocyst.

6. The method of claim 1, wherein the blastocyst-derived stem cell line is stable.

7. The method of claim 1, wherein the blastocyst-derived stem cell line is propagated.

8. The method of claim 7, wherein propagating the blastocyst-derived stem cell line comprises passaging the stem cell line every 4-5 days.

9. The method of claim 7, wherein propagating the blastocyst-derived stem cell line comprises culturing the stem cells with feeder cells of a density of less than about 60,000 cells per cm².

10. The method of claim 9, wherein propagating the blastocyst-derived stem cell line comprises culturing the stem cells with feeder cells of a density of about 45,000 cells per cm².

11. The method of claim 7, wherein the propagation of blastocyst-derived stem cell line comprises passage of the feeder cells at the most 3 times.

12. The method of claim 1, wherein the zona pellucida of the blastocyst has been at least partially digested prior to step ii).

13. The method of claim 12, wherein the zona pellucida of the blastocyst has been at least partially digested with a digestive agent selected from the group comprising acidic reacting substances, enzymes and mixtures thereof.

14. The method of claim 1, wherein step ii) and/or step iv) is performed in an agent that improves the attachment of the blastocysts, and/or the inner cell mass cells to the feeder cells.

15. The method of claim 14, wherein the agent is a hyaluronic acid.

16. The method of claim 1, wherein the feeder cells are embryonic feeder cells.

17. The method of claim 1, wherein the feeder cells employed in steps ii) and iv) are the same or different and the feeder cells originate from animal source.

18. The method of claim 17, wherein the feeder cells are of mouse or human origin.

19. The method of claim 1, wherein the feeder cells are mitotically inactivated.

20. The method of claim 1, wherein the stem cell line

i) exhibits proliferation capacity in an undifferentiated state for more than 21 months when grown on mitotically inactivated embryonic feeder cells;

ii) exhibits normal euploid chromosomal karyotype;

iii) maintains potential to develop into derivatives of all types of germ layers both in vitro and in vivo;

iv) exhibits at least two of the group of molecular markers consisting of OCT-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA 1-60, TRA 1-81, and the protein core of a keratin sulfate/chondroitin sulfate pericellular matrix proteinglycan recognized by the monoclonal antibody GCTM-2;

v) does not exhibit molecular marker SSEA-1 or other differentiation markers;

vi) retains pluripotency and forms teratomas in vivo when injected into immuno-compromised mice; and

vii) is capable of differentiation.

21. A blastocyst-derived stem cell line obtained by the method of claim 1.

22. The method of claim 1, wherein the stem cell line has the ability of differentiating into an insulin producing cells.

23. The method of claim 22, wherein the insulin producing cells form islet-like structures.

24. The method of claim 22, wherein the amount of insulin producing β

-cells which is derived from the pluripotent human BS cell line is higher than 25%.

25. The method of claim 22, wherein the insulin producing cell line produces at least about 300 ng insulin/mg total protein.

26. The method of claim 1, wherein the blastocyst-derived stem cells have the ability to differentiate into differentiated cells, which display the expression of pancreatic cell type markers, including at least one of a group consisting of insulin, Glut-2, Pdx-1, glucokinase, glucagons, and somatostatin.

27. The method of claim 1, wherein the blastocyst-derived stem cells have the ability to differentiate into insulin-producing cells that organize into islet-like structures comprising an inner core of β

-cells surrounded by an outer layer of neuron-type cells, which neuron-type cells display expression of at least one of the following neuronal cell type markers, including neuron-specific β

-III tubulin (TUJ1), NeuN, DoubleCortin, tyrosine hydroxylase, and Map 2.

28. The method of claim 1, wherein the blastocyst-derived stem cells are capable of differentiated into cells, which express at least one neuronal cell type markers selected from the group consisting of, neuron-specific β

-III tubulin (TUJ1), NeuN, DoubleCortin, tyrosine hydroxylase, and Map 2.

29. A preparation of differentiated cells derived from the blastocyst-derived stem cells obtained by the method of claim 1 for preventing or treating pathologies or diseases caused by tissue degeneration.

30. A preparation of differentiated cells derived from the blastocyst-derived stem cells obtained by the method of claim 1 for preventing or treating pathologies or diseases in the pancreas.

31. The preparation of differentiated cells of claim 30, wherein the disease is diabetes.

32. The preparation of differentiated cells of claim 28, wherein the disease is type 1 diabetes.

33. A preparation of differentiated cells derived from the blastocyst-derived stem cell line obtained by the method of claim 1 for preventing or treating pathologies or diseases in the nervous system.

34. The preparation of differentiated cells of claim 33, in which the disease is selected from the group consisting of multiple sclerosis, spinal chord injury, an encephalopathy, Parkinson'"'"'s disease, Huntingdon'"'"'s disease, stroke, a traumatic brain injury, a hypoxia induced brain injury, an ischemia induced brain injury, a hypoglycemic brain injury, a degenerative disorder of the nervous system, a brain tumor, and a neuropathy in the peripheral nervous system.

35. A kit for performing the method of claim 1, comprising human blastocysts with an intact zona pellucida or spontaneously hatched blastocysts, and at least two of the following components in separate compartments:

hyaluronic acid, pronase, BS-cell medium, and human or mouse embryonic feeder cells.

57. The method of claim 1 further comprising propagating the blastocyst-derived stem cell line.

60. The method of claim 9, wherein the step of culturing uses feeder cells at a density less than about 55,000 cells per cm².

61. The method of claim 9, wherein the step of culturing uses feeder cells at a density less than about 50,000 cells per cm².

2. A method for obtaining a pluripotent human blastocyst-derived stem cell line comprising:

i) using a fertilized oocyte of grade 1 or 2 to obtain a blastocyst;

ii) co-culturing the blastocyst with feeder cells to establish one or more colonies of inner cell mass cells;

iii) isolating the inner cell mass cells by mechanical dissection;

iv) co-culturing the inner cell mass cells with feeder cells to obtain a blastocyst-derived stem cell line.

58. The method of claim 2 further comprising propagating the blastocyst-derived stem cell line.

3. A method for obtaining a pluripotent human blastocyst-derived stem cell line comprising:

i) using a fertilized oocyte to obtain a blastocyst of grade A or B;

ii) co-culturing the blastocyst with feeder cells to establish one or more colonies of inner cell mass cells;

iii) isolating the inner cell mass cells by mechanical dissection; and

iv) co-culturing the inner cell mass cells with feeder cells to obtain a blastocyst-derived stem cell line.

59. The method of claim 3 further comprising propagating the blastocyst-derived stem cell line.

4. A method for obtaining a pluripotent human blastocyst-derived stem cell line comprising:

i) using a fertilized oocyte optionally of, grade 1 or 2 to obtain a blastocyst of optionally grade A or B;

ii) co-culturing the blastocyst with feeder cells to establish for establishing one or more colonies of inner cell mass cells,

iii) isolating the inner cell mass cells by mechanical dissection,

iv) co-culturing the inner cell mass cells with feeder cells to obtain a blastocyst-derived stem cell line; and

v) propagation of the blastocyst-derived stem cell line culturing the stem cells with feeder cells of a density of less than about 60,000 cells per cm².

36. A method for producing an essentially pure preparation of insulin-producing differentiated stem cells, comprising:

i) expanding human blastocyst-derived stem cells by growing the blastocyst-derived stem cells on an inactivated feeder cell layer in a suitable medium;

ii) generating blastocyst-derived stem cell bodies by dissociating colonies formed in step i) into smaller aggregates or individual cells, followed by transferring said aggregates or individual cells in to non-adherent containers wherein said aggregate or individual cells are incubated in a suitable medium;

iii) plating the blastocyst-derived stem cell bodies in containers in a suitable medium;

iv) selecting nestin-positive neural precursors in ITFSn medium;

v) expanding pancreatic endocrine progenitor cells in N2-medium comprising B27 media complement and basic fibroblast growth factor; and

vi) changing the medium to a basic fibroblast growth factor-free N2 medium.

37. The method of claim 36, wherein the human blastocyst-derived stem cells are obtained by:

i) using a fertilized oocyte of grade 1 or 2 to obtain a blastocyst of grade A or B;

ii) co-culturing the blastocyst with feeder cells to establish one or more colonies of inner cell mass cells,

iii) isolating the inner cell mass cells by mechanical dissection; and

iv) co-culturing the inner cell mass cells with feeder cells to obtain a blastocyst-derived stem cell line.

38. The method of claim 36, wherein the medium used in step i) is human blastocyst-derived stem cell medium.

39. The method of claim 36, wherein the medium used in step ii) is blastocyst-derived stem cell body medium.

40. The method of claim 36, wherein the medium used in step iii) is blastocyst-derived stem cell body medium.

41. The method of claim 36, wherein nicotinamide is added after step vi).

55. A kit for performing the method of claim 36 comprising at least two of the following components in separate compartments:

mitomycin C, hBS medium, BS cell body medium, ITSFn-medium, N2-medium, B27-media supplement, nicotinamide, and bFGF.

56. The kit of claim 55, further comprising an essentially pure human blastocyst-derived stem cell line obtained by:

i) using a fertilized oocyte of grade 1 or 2 to obtain a blastocyst of grade A or B;

ii) co-culturing the blastocyst with feeder cells to establish one or more colonies of inner cell mass cells;

iii) isolating the inner cell mass cells by mechanical dissection; and

iv) co-culturing the inner cell mass cells with feeder cells to obtain a blastocyst-derived stem cell line.

42. An essentially pure preparation of differentiated stem cells, wherein said stem cells display an expression of pancreatic cell type markers wherein said marker is at least one or more of insulin, Glut-2, Pdx-1, glucokinase, glucagons, or somatostatin.

43. The preparation of claim 42, which is capable of producing at least about 320 ng insulin/mg total protein.

44. The preparation of claim 42, wherein the preparation comprises at least 25% insulin producing cells.

45. The preparation of claim 42, wherein said stem cells are organized into islet-like structures comprising an inner core of β

-cells surrounded by an outer layer of neuron-type cells, wherein the neuron-type cells express at least one of the neuronal cell type markers selected from the group consisting of;

neuron-specific β

-III tubulin (TUJ1), NeuN, DoubleCortin, tyrosine hydroxylase and Map 2.

46. The preparation of claim 42, obtained by:

i) expanding human blastocyst-derived stem cells by growing the blastocyst-derived stem cells on an inactivated feeder cell layer in a suitable medium;

ii) generating blastocyst-derived stem cell bodies by dissociating colonies formed in step i) into smaller aggregates or individual cells, followed by transferring said aggregates or individual cells in to non-adherent containers wherein said aggregate or individual cells are incubated in a suitable medium; and

iii) plating the blastocyst-derived stem cell bodies in containers in a suitable medium;

iv) selecting nestin-positive neural precursors in ITFSn medium;

v) expanding pancreatic endocrine progenitor cells in N2-medium comprising B27 media complement and basic fibroblast growth factor; and

vi) changing the medium to a basic fibroblast growth factor-free N2 medium.

50. An essentially pure preparation of differentiated stem cells of claim 42 for preventing or treating pathologies or diseases in the pancreas.

51. The preparation of claim 50, wherein the disease is diabetes.

52. The preparation of claim 50 wherein in which the disease is type 1 diabetes.

47. An essentially pure preparation of differentiated stem cells, wherein the stem cells express at least one of the neuronal cell type markers selected from the group consisting of:

neuron-specific β

-III tubulin (TUJ1), NeuN, DoubleCortin, tyrosine hydroxylase, or Map 2.

48. The preparation of claim 47 obtained by:

i) expanding human blastocyst-derived stem cells by growing the blastocyst-derived stem cells on an inactivated feeder cell layer in a suitable medium;

ii) generating blastocyst-derived stem cell bodies by dissociating colonies formed in step i) into smaller aggregates or individual cells, followed by transferring said aggregates or individual cells in to non-adherent containers wherein said aggregate or individual cells are incubated in a suitable medium; and

iii) plating the blastocyst-derived stem cell bodies in containers in a suitable medium;

iv) selecting nestin-positive neural precursors in ITFSn medium;

v) expanding pancreatic endocrine progenitor cells in N2-medium comprising B27 media complement and basic fibroblast growth factor; and

vi) changing the medium to a basic fibroblast growth factor-free N2 medium.

53. The preparation of claim 47 for treating pathologies or diseases in the nervous system.

54. The preparation of claim 53, wherein the disease is selected from the group consisting of multiple sclerosis, spinal chord injury, an encephalopathy, Parkinson'"'"'s disease, Huntingdon'"'"'s disease, stroke, a traumatic brain injury, a hypoxia induced brain injury, an ischemia induced brain injury, a hypoglycemic brain injury, a degenerative disorder of the nervous system, a brain tumor, and a neuropathy in the peripheral nervous system.

49. An essentially pure preparation of stem cells obtained by:

i) expanding human blastocyst-derived stem cells by growing the blastocyst-derived stem cells on an inactivated feeder cell layer in a suitable medium;

ii) generating blastocyst-derived stem cell bodies by dissociating colonies formed in step i) into smaller aggregates or individual cells, followed by transferring said aggregates or individual cells in to non-adherent containers wherein said aggregate or individual cells are incubated in a suitable medium; and

iii) plating the blastocyst-derived stem cell bodies in containers in a suitable medium;

iv) selecting nestin-positive neural precursors in ITFSn medium,

v) expanding pancreatic endocrine progenitor cells in N2-medium comprising B27 media complement and basic fibroblast growth factor; and

vi) changing the medium to a basic fibroblast growth factor-free N2 medium.